Key Square Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Key Square Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-207,195	Closed	-$33.9M	–	33
2021 Q2	$33.9M	Buy	+207,195	New	+$31.9M	6.41%	4

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Key Square Capital Management's IBB Position: Q3 2021 in Review

Key Square Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2021, closing a stake of 207,195 shares — an estimated $33.9M sold.

Key Square Capital Management first reported a position in IBB in Q2 2021 and held it in 1 quarter. The position peaked at $33.9M in Q2 2021. 855 funds tracked by Wall St. Rank hold IBB as of Q3 2021.

Key Square Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2021 after selling out during the quarter.
Key Square Capital Management sold 207,195 iShares Biotechnology ETF shares in Q3 2021, an estimated $33.9M.
Key Square Capital Management first reported a position in iShares Biotechnology ETF in Q2 2021 and held it in 1 quarter.
Key Square Capital Management's iShares Biotechnology ETF position peaked at $33.9M in Q2 2021.
855 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2021.

Based on Key Square Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.